Endava Ltd. DAVA 深 沪
等待开盘 11-06 09:30:00 美东时间
1.68
-0.030
-1.75%
华盛通- 最 高1.75
- 今 开1.75
- 成交量 19.65万股
- 最 低 1.6505
- 昨 收 1.71
- 总市值 8877.58万
- 52周最高 7.18
- 市盈率 静 3.60
- 换手率 0.37%
- 52周最低 1.52
- 委 比 52.28%
- 总股本 5284.27万
- 历史最高 172.41
- 量 比 0.53
- 振 幅 5.82%
- 历史最低 1.52
- 每 手 1
- 风险率 1.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Needham Suspends Buy Rating on Endava, Maintains $5 Price Target
Needham suspends Buy rating on Endava (NYSE:DAVA) and Maintains $5 price target
10-12 17:37
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
TD Cowen Reiterates Hold on Endava, Maintains $3.5 Price Target
TD Cowen analyst Bryan Bergin reiterates Endava (NYSE:DAVA) with a Hold and maintains $3.5 price target.
09-22 23:17
William Blair Downgrades Endava to Underperform
William Blair analyst Maggie Nolan downgrades Endava (NYSE:DAVA) from Market Perform to Underperform.
09-22 20:41
Endava Appoints Conor McShane As Interim CFO, Effective Immediately; Places Mark Thurston On Administrative Leave Pending Accounting Investigation
Endava plc (NYSE:DAVA), the technology-driven business transformation group whose AI-native approach combines cutting-edge technology with deep industry expertise, today announced that Conor McShane of AlixPartners LLP, a leading global business advisory firm, has been appointed as Interim Chief Fin...
09-22 05:06
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
TD Cowen Maintains Hold on Endava, Lowers Price Target to $3.5
TD Cowen analyst Bryan Bergin maintains Endava (NYSE:DAVA) with a Hold and lowers the price target from $4 to $3.5.
07-10 00:27
Guggenheim Downgrades Endava to Neutral
Guggenheim analyst Jonathan Lee downgrades Endava (NYSE:DAVA) from Buy to Neutral.
05-27 20:57
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
